Chemotherapeutic targeting of myeloid-derived suppressor cells

Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selec...

Descripción completa

Detalles Bibliográficos
Autores principales: Alizadeh, Darya, Katsanis, Emmanuel, Larmonier, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960296/
https://www.ncbi.nlm.nih.gov/pubmed/24653963
http://dx.doi.org/10.4161/onci.27359
Descripción
Sumario:Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.

Ejemplares similares